Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.

Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.

Item
http://www.wikidata.org/entity/Q51032125
Polycythemia vera--a case report and discussion on pathogenic mechanisms of increased thrombosisComprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders.Cerebral thrombosis and myeloproliferative neoplasms.Haemostatic Profile in Patients of Myeloproliferative Neoplasms-A Tertiary Care Centre Experience.Thrombophilia in ischemic strokesEPCR Levels in Chronic Myeloproliferative Diseases and Their Association with Thromboembolic Events: A Case-Control Study.Treatment related changes in antifibrinolytic activity in patients with polycythemia vera.Off-pump myocardial revascularization in a high-risk patient with essential thrombocythemia.Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders.Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.Plasma Concentrations of Protein Z and Protein Z-Dependent Protease Inhibitor in Patients With Essential Thrombocythemia.Markers of Endothelial and Platelet Status in Patients with Essential Thrombocythemia and Polycythemia Vera.Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.Erythrocyte Deformability is Reduced and Fragility increased by Iron Deficiency.Relationship between clotting activity and phosphatidylserine expression on erythrocyte membranes in polycythemia vera patients with the JAK2 V617F mutation.
P2860

Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.

Item
http://www.wikidata.org/entity/Q51032125
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Reduction of antithrombin III, ...... emia patients with thrombosis.
@en
Reduction of antithrombin III, ...... emia patients with thrombosis.
@nl
type
label
Reduction of antithrombin III, ...... emia patients with thrombosis.
@en
Reduction of antithrombin III, ...... emia patients with thrombosis.
@nl
prefLabel
Reduction of antithrombin III, ...... emia patients with thrombosis.
@en
Reduction of antithrombin III, ...... emia patients with thrombosis.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Reduction of antithrombin III, ...... emia patients with thrombosis.
@en
P2093
P2860
P304
P31
P356
10.1002/(SICI)1096-8652(199605)52:1<14::AID-AJH3>3.0.CO;2-9
P433
P478
P577
P698
P921